KRAS Exon 4 Mutation Analysis

Clinical Significance

This assay complements the standard KRAS Mutation Analysis of exons 2 and 3. Mutations in exon 4 are detected in approximately 1-4% of colorectal cancers. Exon 4 analysis is appropriate for detecting activating mutations that may confer resistance to EGFR-targeted inhibitors and predicts sensitivity to MEK inhibition.

Specimen Requirements

FFPE tissue: Paraffin block

Transport And Storage

 Refrigerate, and use cold pack for transport, cold pack should not be in direct contact with specimen.

Collection Instructions

Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.

Minimum Volume

Neonatal Volume

Reference Range:

Refer to Interpretive Results

Methodology:

• Molecular

Clinical Significance

This assay complements the standard KRAS Mutation Analysis of exons 2 and 3. Mutations in exon 4 are detected in approximately 1-4% of colorectal cancers. Exon 4 analysis is appropriate for detecting activating mutations that may confer resistance to EGFR-targeted inhibitors and predicts sensitivity to MEK inhibition.

CDM

01441276

CPT Coding

81276